Back to search results

BSAFE Study for Overdose Prevention

This study, called BSAFE, is testing a new approach to help people who use stimulants (like cocaine or methamphetamine) reduce their risk of accidental overdose from fentanyl. The BSAFE intervention involves counseling, safety text messages, and connecting you to care. It's being compared to an "attention control" group that watches videos. To join, you must be 18 or older, use cocaine or methamphetamine frequently, and have a urine test showing these drugs but no opioids/fentanyl. The study aims to see if BSAFE can lower the number of accidental fentanyl overdoses and unintentional fentanyl use over 16 months. The current recruitment status is unclear.

Study design
This is a randomized study comparing the BSAFE intervention to an attention control. It plans to enroll 160 participants.
What's involved
The intervention will include counseling sessions, reminder safety text messages, and linkage to care. The attention control group will watch videos.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 16 months to measure the incidence of opioid overdose and unintentional fentanyl use.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07219082

Behavioral Safety and Fentanyl Education: BSAFE

Recruiting
NAAges 18+InterventionalPrevention
San Francisco Department of Public Health
~160 participants
Updated 2026-08-18 on ClinicalTrials.gov
What's tested:BSAFE InterventionAttention control

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of opioid overdose due to unintentional fentanyl use
Measured over 16 months
+1 more outcome measured

Conditions

Drug Overdose
Drug Overdose Accidental

Explore related trials

Accidental overdoseOverdose

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Alexander Bazazi, MD, PhD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

Phillip O Coffin, MD, MIA
[email protected]
(628) 217-6282
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Incidence of opioid overdose due to unintentional fentanyl use16 months

    Incidence of overdose will be measured by a composite measure of non-fatal and fatal overdose count collected by blinded assessors from Timeline Follow-Back (TLFB) every 4 months and vital record linkage for overdose fatalities.

  • Incidence of unintentional fentanyl use16 months

    Incidence of biomarker-confirmed unintentional fentanyl use, as determined by hair sampling for fentanyl and related analogues collected every 4 months.